John B O'Connell, Charles K Moore, H Chris Waterer Dilated cardiomyopathy continues to be a serious clinical problem with about 20 000 new patients affected in the United States each year. By definition, the cause of injury to the myocardium is unknown.' Consequently, treatment is purely symptomatic because it cannot be specifically directed toward aetiology. In most cases, the major symptomatic presentations of dilated cardiomyopathy, arrhythmia, embolic phenomena, and congestive heart failure, are successfully managed, at least initially, by conventional treatment. However, if myocardial injury persists or is so severe that conventional treatment does not palliate the symptoms, cardiac transplantation remains the only viable alternative. In fact, 50% of those undergoing cardiac transplantation have dilated cardiomyopathy. In the present paper we describe the conventional management of dilated cardiomyopathy and discuss new approaches that may prolong survival and reduce morbidity.
Management of congestive heart failure VOLUME OVERLOAD AND EXERCISE The management of congestive heart failure in patients with dilated cardiomyopathy differs little from the management of patients with specific heart muscle diseases or other causes of left ventricular dysfunction (table  1) . Volume overload owing to salt and water retention is prominent. Sodium and water restriction are appropriate and diuretics are indicated. Loop diuretics (frusemide, bumetanide, etc) are preferred. When the dose of loop diuretics is increasing and the response diminishing, the addition of a thiazide (metolazone) to the loop diuretic may be of additional benefit.' With low cardiac output The selective adrenergic agonist, dobutamine, is effective for the short-term management of congestive heart failure or exacerbations of chronic heart failure when given as an intravenous infusion to doses of 10 /ug/kg/min.23 Attempts to develop oral adrenergic agonists for the long-term treatment of heart failure have been frustrated by the rapid development of tolerance,24 which presumably is associated with down regulation of adrenergic receptors. In patients with severe congestive heart failure, the beneficial effect of brief (three to four day) infusions of dobutamine may be sustained. 25 group.bmj.com on June 26, 2017 -Published by http://heart.bmj.com/ Downloaded from and quality of life improved significantly. 33 The high dose arm (120 mg) increased mortality. Neutropenia occurred in 2-5% of the patients receiving the agent. This drug is currently under continued phase III clinical trials. An intravenous analogue, OPC18790, is entering clinical trials.
ft Blockers
The adverse effect of neurohormonal activation is underscored by the efficacy of ft adrenergic blockade in the treatment of congestive heart failure. The metoprolol in dilated cardiomyopathy (MDC) trial showed a reduction in cardiovascular morbidity and improved ejection fraction in more than 300 patients with dilated cardiomyopathy and congestive heart failure.34 Although tolerance to ft adrenergic blockade is quite good overall, the dose titration phase can exacerbate congestive heart failure in some patients and so delay the achievement of the maximum targeted dose.
Some new ft blockers have vasodilating properties that improve tolerance and reduce the difficulty with dose titration. Vasodilation by bucindolol is mediated by a nitrile-like component, and carvedilol has weak a blocking properties.35 Compared with metoprolol, short-term treatment with carvedilol increased the cardiac index, decreased systemic vascular resistance, and decreased filling pressures-a reflection of the vasodilator effect. Long-term treatment with bucindolol produced a sustained increase in ejection fraction. 36 The mechanism of action of ft blockade is unknown. Initially, it was thought that up regulation of the ft receptor that resulted from long-term treatment with metoprolol was the major mechanism of action.37 However, clinical and haemodynamic improvement was detected with carvedilol treatment in the absence of up regulation of these receptors.38 Perhaps the major mechanism of action is simply blockade of the receptors and a reduction of the adverse effects of catecholamines on the failing human heart. Vesnarinone and ft blockade may prove to be major additions to the treatment of dilated cardiomyopathy. Additionally, if the definitive clinical trials show survival similar to the improvement reported in the preliminary studies, the outcome with this approach in patients with NYHA class m symptoms will be comparable to cardiac transplantation.
Annicoagulation
Patients with dilated cardiomyopathy are susceptible to thromboembolic phenomena, because of poor peripheral perfusion and low flow, and to the formation of mural thrombi, particularly when the ejection fraction is <30%. 39 The likelihood of an embolic episode is approximately 30% over a two year follow up in patients with a low ejection fraction and decompensated congestive heart failure. Therefore, it is logical to consider long-term oral anticoagulant treatment in these patients. However, regulation of anticoagulant treatment may be particularly difficult because the patients who are most likely to benefit, those with poorly controlled congestive heart failure, have hepatic congestion and subsequent autoanticoagulation. Recently, the broad based recommendation for chronic anticoagulant treatment in patients with dilated cardiomyopathy has been questioned because no prospective clinical trials showing its efficacy and defining its morbidity have been completed. Therefore, long-term oral anticoagulation is commonplace but not of proven benefit.
Antiarrhythmic treatment Ventricular arrhythmias are common in patients with dilated cardiomyopathy. In fact, over 70% of these patients have non-sustained ventricular tachycardia during ambulatory monitoring. 40 The arrhythmias may be inducible in the electrophysiology laboratory but a correlation between ventricular arrhythmias and sudden death in dilated cardiomyopathy has never been confirmed. 4 better pharmacological treatment will greatly inprove the outcome of patients with dilated cardiomyopathy.
